• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 208

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic Access for Veterans

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business...

“Neuropharmacology: Psychedelics on the Brain” – Jim Harris, Rachel Zoeller, DPT, David W. Mcmillan, Ph.D., and Manesh Girn, Ph.D.

Wesana Health Announces Closing of PsyTech Acquisition

Levitee Labs Commences Trading in U.S. Under Ticker LVTTF

CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

Red Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering...

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

No, VR Will Not Give You A Psychedelic Trip

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year...

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Glutamate’s Role in Rapidly-Acting Antidepressants

Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its...

1...207208209...286Page 208 of 286

EDITOR PICKS

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic...

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©